



Milton Keynes Clinical Commissioning Group

Milton Keynes Community Health Services

Contraception

Oestrogen content	Progestogen content	Recommended Formulary Brand	Comments
Ethinylestradiol	Desogestrel	Munalea® 20/150	Munalea 20/150 is a cost-
20 micrograms	150 micrograms	Gedarel® 20/150	effective choice
		Alternative brand:	-
		Mercilon® (Amber 2)	A:
Ethinylestradiol	Gestodene	Aidulan® 20/75	Aidulan® 20/75 is a cost-
20 micrograms	75 micrograms	Millinette® 20/75	effective choice
		Alternative brand:	1
		Femodette® (Amber 2)	
Ethinylestradiol 20 micrograms	Norethisterone acetate 1mg	Loestrin® 20	
Ethinylestradiol	Desogestrel	Munalea® 30/150	Munalea 30/150 is a cost-
30 micrograms	150 micrograms	Gedarel® 30/150	effective choice
30 micrograms	150 micrograms	Gedarer 30/130	
		Alternative brands:	
		Marvelon® (Amber 2)	
Ethinylestradiol	Drospirenone 3mg	Yiznell® (Amber 2)	Yiznell and Lucette are the
30 micrograms		Lucette® (Amber 2)	cost effective equivalent to Yasmin®;
		Alternative brands:	To be used 3 rd or 4 th line for
		Yasmin® (Amber 2)	women intolerant to other
			contraceptives
Ethinylestradiol	Gestodene	Aidulan® 30/75	Aidulan® 30/75 is a cost-
30 micrograms	75 micrograms	Millinette® 30/75	effective choice
		Alternative brands:	-
		Femodene® (Amber 2)	
Ethinylestradiol	Levonorgestrel	Maexeni®	Maexeni® is a cost-effective
30 micrograms	150 micrograms	Rigevidon®	choice
		Alternative brands:	-
		Microgynon® 30	
		(Amber 2)	
Ethioudoctes dial	Norothistorono	Ovranette® (Amber 2)	
Ethinylestradiol 30 micrograms	Norethisterone acetate 1.5mg	Loestrin® 30	

Written by: Dupe Fagbenro, Pharmacist MKCCG	Checked by: Janet Corbett, Head of Medicines	
	Management, MKCCG	
Status: Version 1	Approved by: MKPAG Sept 2018	
Date written: August 2018	Renewal date: August 2021	







Milton Keynes Community Health Services

Ethinylestradiol	Norgestimate	Cilique®	Cilique is a cost-effective
35 micrograms	250 micrograms		choice
		Alternative brand:	
		Cilest® (Amber 2)	
Ethinylestradiol	Norethisterone	Brevinor®	
35 micrograms	500 micrograms		
Ethinylestradiol	Norethisterone	Norimin®	
35 micrograms	1mg		

Combined Oral Contraceptives Monophasic 28-day preparations			
Oestrogen content Progestogen content Recommended Comments			Comments
		Formulary Brand	
Ethinylestradiol	Gestodene	Femodene® ED	
30 micrograms	75 micrograms		
Ethinylestradiol	Levonorgestrel	Microgynon 30	
30 micrograms	150 micrograms	ED®	

Combined Oral Contraceptives Phasic 21-day preparation			
Oestrogen content Progestogen content		Recommended	Comments
		Formulary Brand	
Ethinylestradiol	Levonorgestrel		
30 micrograms	50 micrograms		
Ethinylestradiol	Levonorgestrel	Logynon®	
40 micrograms	75 micrograms		
Ethinylestradiol	Levonorgestrel		
30 micrograms	125 micrograms		

Combined Oral Contraceptives Phasic 28-day preparation			
Oestrogen content	Progestogen content	Recommended	Comments
		Formulary Brand	
Ethinylestradiol	Levonorgestrel		
30 micrograms	50 micrograms		
Ethinylestradiol	Levonorgestrel	Logynon ED®	
40 micrograms	75 micrograms		
Ethinylestradiol	Levonorgestrel		
30 micrograms	125 micrograms		

Combined Transdermal Patch			
Oestrogen content	Progestogen content	Recommended	Comments
		Formulary Brand	
Ethinylestradiol 33.9 micrograms per 24 hours	Norelgestromin 203 micrograms per 24 hours	Evra® Patches (Amber 2)	May be of value in women who are poor compliers with oral contraceptives. Woman should have tried at
			least 2 oral contraceptives

Written by: Dupe Fagbenro, Pharmacist MKCCG	Checked by: Janet Corbett, Head of Medicines	
	Management, MKCCG	
Status: Version 1	Approved by: MKPAG Sept 2018	
Date written: August 2018	Renewal date: August 2021	





Milton Keynes Community Health Services



Vaginal Ring				
Oestrogen	Progestogen	Recommended	Comments	
content	content	Formulary Brand		
Releases Ethinylestradiol 15 micrograms per 24 hours over a period of 3 weeks.	Releases Etonogestrel 120 micrograms per 24 hours over a period of 3 weeks.	NuvaRing® (Amber 2) NuvaRing contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol.	The ring releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg respectively per 24 hours, over a period of 3 weeks. It is restricted to patients unable to use other methods of contraception and for prescribing by specialists in reproductive health	

Progestogen-Only Pills			
Progestogen content	Recommended	Comments	
	Formulary Brand		
Desogestrel	Desogestrel	Prescribe generically	
75 micrograms			
Norethisterone	Norethisterone	Prescribe generically for all new	
350 micrograms		patients	
	Alternative brand:		
	Noriday® (Amber 2)		

Emergency Contraception

It is possible that a higher body-weight or BMI could reduce the effectiveness of oral emergency contraception, particularly levonorgestrel; if BMI is greater than 26 kg/m² or body-weight is greater than 70 kg, it is recommended that either ulipristal acetate or a double dose of levonorgestrel [unlicensed indication] is given. It is unknown which is more effective.

Further information on Emergency Contraception can be obtained from: The Faculty of Sexual and Reproductive Healthcare. Clinical guidance. March 2017.

 $\underline{www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-emergency-contraception-march-2017$

Progestogens	Levonorgestrel 1.5mg	FIRST CHOICE oral preparation for patients presenting within 72 hours of unprotected sexual intercourse. Prescribe generically Available via PGD through some pharmacies across Milton Keynes, free of charge to all. DO NOT PRESCRIBE AS THE OTC PREPARATION: Levonelle One Step® (as over twice the cost of the POM product.)
Progesterone receptor	Ulipristal acetate 30mg	Ulipristal is licensed for emergency contraception within 120 hours (5 days) after unprotected sexual intercourse
modulators	(EllaOne®) (Amber 2)	(UPSI). Patients presenting between 72 hours and 120 hours may

Written by: Dupe Fagbenro, Pharmacist MKCCG	Checked by: Janet Corbett, Head of Medicines	
	Management, MKCCG	
Status: Version 1	Approved by: MKPAG Sept 2018	
Date written: August 2018	Renewal date: August 2021	







Milton Keynes Community Health Services

	be offered the choice of ulipristal acetate or intrauterine			
		·		
		device and the risks and benefits of each method should be		
		discussed with the patient.		
		Pregnancy should be excluded before ulipristal is taken.		
Intra uterine POP system				
Levonorgestrel 19.5mg as Kyleena®		Prescribe by brand name		
		Intra-uterine device which releases levonorgestrel and		
		offers contraception for up to 5 years		
Levonorgestrel 52mg as Mirena®		Prescribe by brand name		
		Intra-uterine device which releases levonorgestrel and		
		offers contraception for up to 5 years		
Levonorgestrel 13.5mg as Jaydess®		Prescribe by brand name		
		Intra-uterine device which releases levonorgestrel and		
		offers contraception for up to 3 years		

Long-acting reversible contraception (LARC)				
PHE Funded				
LARC methods are more cost-effective than COC pill even at one year.				
Features of LARC to discuss with women can be found on the NICE website here:				
https://www.nice.org.uk/guidance/cg30/chapter/appendix-a-features-of-the-larc-methods-				
to-discuss-with-women				
The Choice of method for different groups of women can be found on the NICE website				
here: https://www.nice.org.uk/guidance/cg30/chapter/appendix-b-choice-of-method-for-				
different-groups-of-women				
Products:				
Medroxy-progesterone as Depo-Provera®				
150mg/ml prefilled syringe				
Medroxy-progesterone as Sayana Press®	Patients can self-inject			
104mg/0.65ml susp in pre-filled injector				
Etonogestrel as Nexplanon®	Subdermal implant which offers			
68mg implant	contraception for 3 years			

Useful resources

- 1. UK Medical Eligibility Criteria for Contraceptive Use; UKMEC 2016. Accessed via https://www.fsrh.org/standards-and-guidance/documents/ukmec-2016/ (October 2018)
- 2. Faculty of Sexual & Reproductive Healthcare guidelines. Accessed via https://www.fsrh.org/standards-and-guidance/ (June 2018)
- 3. St John's wort: interaction with hormonal contraceptives, including implants. Accessed via https://www.gov.uk/drug-safety-update/st-john-s-wort-interaction-with-hormonal-contraceptives-including-implants (June 2018)
- 4. Is there a lactose-free contraceptive? Accessed via https://www.sps.nhs.uk/articles/is-there-a-lactose-free-oral-contraceptive-2/?UNLID=96143088120186695914 (June 2018)

Written by: Dupe Fagbenro, Pharmacist MKCCG	Checked by: Janet Corbett, Head of Medicines	
	Management, MKCCG	
Status: Version 1	Approved by: MKPAG Sept 2018	
Date written: August 2018	Renewal date: August 2021	